Literature DB >> 6295339

Third-generation cephalosporins for polymicrobial surgical sepsis.

H H Stone, P R Strom, T C Fabian, W E Dunlop.   

Abstract

During 31 months of study, 808 patients with polymicrobial surgical infection were randomized for antibiotic therapy between a third-generation cephalosporin (moxalactam disodium [149], cefotaxime sodium [125], and cefoperazone sodium [141]) and the combination of gentamicin sulfate plus clindamycin (393). Results based on antibiotic therapy included the following: cure in 83% given cephalosporin, 73% with antibiotic combination; control but recurrent sepsis in 7% and 15%; and failure in 4% and 8%, respectively. Such data support the tenet that third-generation cephalosporins are at least equal, if not superior, to the combination of gentamicin plus clindamycin for treatment of polymicrobial surgical sepsis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6295339     DOI: 10.1001/archsurg.1983.01390020047009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  7 in total

Review 1.  Management of secondary peritonitis.

Authors:  D H Wittmann; M Schein; R E Condon
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

Review 2.  Piperacillin/tazobactam in the treatment of polymicrobial infections.

Authors:  S L Gorbach
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

Review 3.  Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

Authors:  J S Solomkin; J L Meakins; M D Allo; E P Dellinger; R L Simmons
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

Review 4.  Operative and nonoperative therapy of intraabdominal infections.

Authors:  D H Wittmann
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

5.  Calculated empiric antimicrobial therapy for mixed surgical infections.

Authors:  D H Wittmann; J M Bergstein; C Frantzides
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 6.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

7.  Preventative antibiotics for penetrating abdominal trauma--single agent or combination therapy?

Authors:  B A Bivins; L Crots; V J Sorensen; F N Obeid; H M Horst
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.